乾眼症治療市場：依產品類型、通路和地區分類

Dry Eye Syndrome Treatment Market, By Product Type, By Distribution Channel, By Geography

出版日期: 2026年02月09日 | 出版商:

Coherent Market Insights | 英文 152 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

據估計，2026年乾眼症治療市場規模為132.9億美元，預計2033年將達到384.2億美元。預計2026年至2033年，該市場將以16.4%的複合年成長率成長。

分析範圍		分析詳情
基準年	2025	市場規模（2026 年）	132.9億美元
效能數據	2020-2024	預測期	2026-2033
預測期（2026-2033 年）複合年成長率	16.40%	預計金額（2033 年）	384.2億美元

乾眼症（DES），也稱為乾燥性角膜疾病或角膜乾燥症，是一種常見疾病，當淚液無法充分潤滑眼球時就會發生。乾眼症患者可能出現眼表損傷、淚膜不穩定和視力障礙。淚膜覆蓋眼球表面，由三層交織的物質組成。最外層的脂質層由瞼板腺分泌，有助於防止淚液蒸發並使淚液均勻分佈。中間的濃稠水層由淚腺分泌，最內層的親水性黏蛋白層則由結膜杯狀細胞和眼表上皮細胞分泌。乾眼症的病因眾多，可分為原發性和續發性。乾眼症的發生可能由多種因素引起，包括發炎性疾病（血管性、過敏性等）、環境因素（過敏原、香菸煙霧、乾燥氣候等）、荷爾蒙失衡（例如閉經婦女或接受荷爾蒙補充療法的患者）以及配戴隱形眼鏡。其他乾眼症的原因還包括某些疾病，例如類風濕性關節炎、修格蘭氏症候群、甲狀腺疾病、紅斑性狼瘡、瞼緣炎（眼瞼炎腫脹和發紅）、瞼內翻（眼瞼向內翻轉）、瞼外翻（眼瞼向外翻轉）以及暴露於煙霧、風或非常乾燥的氣候中。

市場動態

新的乾眼症治療方法不斷湧現，許多新藥也等候核准核准。強大的產品平臺蘊藏著巨大的成長機遇，預計在預測期內，多個在研發線產品的核准將推動市場成長。例如，2021年10月，專注於眼科疾病治療方法研發和商業化的生物製藥公司Oyster Point Pharma宣布，其0.03毫克鹽酸伐Varenicline鼻噴霧TYRVAYA已獲得美國食品藥物管理局（FDA）核准，用於治療乾眼症的症狀和體徵。 TYRVAYA鼻噴霧是一種選擇性膽鹼能促效劑，可激活基礎淚液分泌，每日兩次，每次向每個鼻孔鼻噴霧。

本研究的主要特點：

本報告對全球乾眼症治療市場進行了詳細分析，以 2021 年為基準年，給出了預測期（2022-2030 年）的市場規模和復合年成長率。
本報告指出了各個細分市場的潛在商機，並說明了該市場中具有吸引力的投資提案矩陣。
此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
本報告根據以下參數對全球乾眼症治療市場的主要參與者進行了分析：公司概況、產品系列、主要亮點、財務表現和策略。
透過利用本報告中提出的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
這份全球乾眼症治療市場報告的目標受群眾外包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師等產業相關人員。
透過對全球乾眼症治療市場進行分析時所使用的各種策略矩陣，相關人員將能夠更輕鬆地做出決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太地區
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第7章競爭情勢

AbbVie Inc.
Novartis AG
Bausch Health Companies Inc.
Johnson &Johnson, Inc.
I-MED Pharma inc.
Santen Pharmaceutical Co., Ltd
AFT Pharmaceuticals
Novaliq GmbH
Otsuka Pharmaceutical Co., Ltd.
Sun Pharmaceutical Industries, Inc.
Teva Pharmaceutical Industries Ltd.
Mitotech, SA
Viatris Inc.

簡介目錄

Product Code: CMI1173

Dry Eye Syndrome Treatment Market is estimated to be valued at USD 13,290 Mn in 2026 and is expected to reach USD 38,420 Mn by 2033, growing at a compound annual growth rate (CAGR) of 16.4% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 13,290 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	16.40%	2033 Value Projection:	USD 38,420 Mn

Dry eye syndrome (DES) is also known as keratisis sicca and keratoconjunctivitis sicca. Dry eye disease is a common condition that occurs when your tears aren't able to provide adequate lubrication for your eyes. Patients suffering from DES show damage to the ocular surface, instability in the tear film, and visual disturbance. Tear film covers the ocular surface which is made up of three intertwined layers, a superficial lipid layer produced by meibomian glands assist in reducing tear evaporation and uniform tear spreading, middle thick aqueous layer produced from lacrimal glands, and the innermost hydrophilic mucin layer produced from goblet cells of conjunctiva and epithelium of ocular surface. Dry eye syndrome is associated with a long list of causes which can be divided into primary and secondary. Dry eye may develop secondary to inflammatory disease (e.g. vascular, allergic), environmental conditions (e.g. allergens, cigarette smoke, dry climate), hormonal imbalance (e.g. perimenopausal women and patients under hormone replacement therapy), and contact lens wear. Other causes of dry eye are certain diseases, such as rheumatoid arthritis, Sjogren's syndrome, thyroid disease, and lupus Blepharitis (when eyelids are swollen or red), Entropion (when eyelids turn in), ectropion (eyelids turn outward) and being in smoke, wind or a very dry climate.

Market Dynamics

New dry eye therapies are introduced in the market with several new medications in the pipeline seeking approval. Strong product pipeline offers great market growth opportunity as approval of numerous pipeline products is expected to drive the market growth during the forecast period. For instance, in October 2021, Oyster Point Pharma, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of therapies to address ophthalmic disease, announce the U.S. Food and Drug Administration (FDA) approval for TYRVAYA (varenicline solution) Nasal Spray 0.03 mg, for the treatment of the signs and symptoms of dry eye disease. YRVAYA Nasal Spray is a selective cholinergic agonist delivered twice daily as an aqueous nasal spray into each nostril to activate basal tear production.

Key features of the study:

This report provides in-depth analysis of the global dry eye syndrome treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global dry eye syndrome treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include AbbVie Inc., Novartis AG, Bausch Health Companies Inc., Johnson & Johnson, Inc., I-MED Pharma inc., Santen Pharmaceutical Co., Ltd, AFT Pharmaceuticals, Novaliq GmbH, Otsuka Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries, Inc., Teva Pharmaceutical Industries Ltd., Mitotech, SA, Viatris Inc., among other prominent players
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global dry eye syndrome treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dry eye syndrome treatment market

Market Segmentation

Product Type Insights (Revenue, USD Mn, 2026 - 2033)
- Cyclosporine
- Oral Corticosteroid
- Artificial Tears
- Omega Supplements
- Punctual Bags
- Other
Distribution Channel Insights (Revenue, USD Mn, 2026 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Supermarket/ Hypermarket
- Online Pharmacies
Regional Insights (Revenue, USD Mn, 2026 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- AbbVie Inc.
- Novartis AG
- Bausch Health Companies Inc.
- Johnson & Johnson, Inc.
- I-MED Pharma inc.
- Santen Pharmaceutical Co., Ltd
- AFT Pharmaceuticals
- Novaliq GmbH
- Otsuka Pharmaceutical Co., Ltd.
- Sun Pharmaceutical Industries, Inc.
- Teva Pharmaceutical Industries Ltd.
- Mitotech, SA
- Viatris Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Product Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Recent Developments
Acquisitions and Partnerships Scenario
Technology Overview
Regulatory Scenario
PEST Analysis
Porter's Analysis

4. Global Dry Eye Syndrome Treatment Market, By Product Type, 2026-2033, (USD Mn)

Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Cyclosporine
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Oral Corticosteroid
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Artificial Tears
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Omega Supplements
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Punctual Bags
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Others
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

5. Global Dry Eye Syndrome Treatment Market, By Distribution Channel, 2026-2033, (USD Mn)

Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Hospital Pharmacies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Retail Pharmacies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Supermarket/ Hypermarket
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Online Pharmacies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

6. Global Dry Eye Syndrome Treatment Market, By Region, 2026-2033, (USD Mn)

Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
North America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - U.S.
  - Canada
Latin America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - North Africa
  - Central Africa
  - South Africa

7. Competitive Landscape

AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Bausch Health Companies Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Johnson & Johnson, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
I-MED Pharma inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Santen Pharmaceutical Co., Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
AFT Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Novaliq GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Otsuka Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sun Pharmaceutical Industries, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Mitotech, SA
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Viatris Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies